Viracept
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Nelfinavir
- Made by
- Roche Registration Ltd.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older. In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Roche Registration Ltd. |
|---|---|
| Active substance | Nelfinavir |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AE04 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 1998-01-22 |
| Last updated by the regulator | 2014-06-10 |
| EMA product number | EMEA/H/C/000164 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).